Loading
Nanoparticle-based Drug Delivery / Cancer, Hypoxia, and Metabolism / Nanoplatforms for Cancer Theranostics · Journal article
Journal of Nanobiotechnology · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
A preclinical study reports design and synthesis of a novel biomimetic cascaded nanoreactor (DCM@MCuH@MnCO) that integrates carbon monoxide gas therapy with copper-mediated chemodynamic therapy, engineered to remodel the tumor microenvironment by depleting glutathione and generating hydrogen peroxide and reactive oxygen species. The material demonstrated cytotoxic and anti-tumor activity in vitro and in vivo, but this is a proof-of-concept study with no human data, no direct comparison to standard prostate cancer treatments, and no quantified efficacy metrics.
Preclinical laboratory study with in vitro and in vivo components. Prostate cancer cell lines and animal models bearing prostate cancer tumors. Intervention: Biomimetic cascaded nanoreactor (DCM@MCuH@MnCO) integrating copper-catechol network, H₂O₂-sensitive manganese carbonyl, mesoporous carbon hollow spheres, and tumor cell membrane modification.
The nanoreactor DCM@MCuH@MnCO was constructed to integrate copper-catechol coordination, H₂O₂-sensitive manganese carbonyl, and tumor cell membrane coating to enhance targeting The nanoreactor design couples GSH depletion and in situ H₂O₂ and CO generation to drive synergistic CO therapy and chemodynamic therapy The material induced mitochondrial damage and ROS storm within tumor cells, resulting in effective cell killing both in vitro and in vivo
No human clinical data or biocompatibility/toxicity assessment in humans reported
This is a laboratory-stage development and does not provide evidence for clinical use. Preclinical validation alone does not support clinical decision-making; translation to human studies and direct comparison with standard-of-care therapies would be required to assess clinical potential.
Preclinical study demonstrating a novel nanomaterial design with in vitro and in vivo efficacy in cancer models, but lacking clinical translation, mechanistic validation in human tissue, or comparison to standard therapies.
As stated by the source record.
This is a laboratory-stage development and does not provide evidence for clinical use. Preclinical validation alone does not support clinical decision-making; translation to human studies and direct comparison with standard-of-care therapies would be required to assess clinical potential.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Prostate cancer (PCa) is the most prevalent malignant tumor in the male genitourinary system. Carbon monoxide (CO) gas therapy and chemodynamic therapy (CDT) have emerged as alternative treatments for cancer. However, the therapeutic efficacy of both approaches is constrained by the insufficient endogenous hydrogen peroxide (H 2 O 2 ) supply and the overexpression of protective glutathione (GSH) in the tumor microenvironment (TME). Herein, we developed a biomimetic cascaded nanoreactor (DCM@MCuH@MnCO) for synergistically combining CO-mediated gas therapy with CDT driven by depletion of GSH and self-supply of H 2 O 2 in the tumor. DCM@MCuH@MnCO was constructed by integrating a copper-catechol coordinated network (CuH) and H 2 O 2 -sensitive manganese carbonyl (MnCO) within the mesoporous carbon hollow spheres (MCHS), and further modifying the surface with tumor cell membranes (DCM) to enhance its tumor-targeting ability. The CuH in the nanoreactor can disassemble, triggered by continuous consumption of GSH, releasing pro-oxidative catechol ligands to generate H 2 O 2 for TME remodeling. Subsequently, MnCO decomposes on demand to release CO in situ while copper ions (Cu + ) convert H 2 O 2 into reactive oxygen species (ROS) via a Fenton-like reaction. These events cooperatively cause mitochondrial damage and induce a lethal ROS storm within cells, ultimately effectively killing tumor cells both in vitro and in vivo. This study demonstrates significant prospects for CO therapy and CDT, offering a novel and promising strategy for efficient PCa treatment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.